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Tumefactive Multiple Sclerosis, an Uncommon Variant
with Several Mimics
David Macon DO, Family Medicine, Henry Ford Health System, Detroit,
Michigan

Introduction
Acute onset extremity weakness is a common and concerning complaint, which requires a
timely workup to rule out both ischemic etiologies, as well as inflammatory, infectious,
iatrogenic or other organic causes. Those cases which are due to inflammatory
demyelinating processes are diagnosed via clinical course, typical imaging findings, as well
as laboratory results. Once an inflammatory process has been identified, treatment typically
begins with steroids, however long term treatment and prevention of exacerbations is often
complicated by atypical presentations and an unsure diagnosis. In those cases where
diagnosis is unclear, biopsy may be required.

Neuroimaging
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Case Description
A 39 year old caucasian male with no significant past medical or family history, presented to
the Henry Ford Macomb family medicine residency clinic with a 4 day history of right sided
upper extremity weakness. The patient denied any preceding trauma or illness, and stated the
symptoms were present after waking in the morning. The patient’s wife reported that he
seemed to be acting slightly confused and walking with an altered gait, though he denied
these symptoms. Two days prior to this office visit, the patient was seen in the ED for this
complaint, where a stroke work up including CT of the head and neck was performed. No
acute process was identified during this encounter, however non specific hypoattenuation was
noted in the left frontal lobe. The patient left the hospital AMA before any further neurologic
workup was completed.

MRI demonstrated a contrast enhancing 4.8 x
4.8 x 5.2 cm mass of the left frontal lobe, with
extension to the contralateral frontal lobe via
the body of the corpus callosum. T1 weighted
imaging reveals a hypointense lesion, as
depicted in image A. T2 weighted imaging
demonstrates hyperintensity, has well as
partial ring enhancement, depicted in image B.
There was no appreciable mass effect from the
lesion in question.

C

On initial examination the patient was anxious, but otherwise appropriate and in no acute
distress. Cardiopulmonary examination was unremarkable. There was diffuse weakness of the
right upper extremity, with strength testing ranging from 3/5-4/5 from the hand to shoulder.
No other strength deficits were appreciated on examination. Cranial nerves II-X and XII were
intact, with subtle weakness of the R trapezius suggestive of CN XI deficit. Deep tendon
reflexes of both upper and lower extremities, bilaterally, were 2/4 where tested. Sensation and
two point discrimination were intact bilaterally in upper and lower extremities.
EMG of the right upper extremity and MRI of the brain were ordered, with the EMG
demonstrating idiopathic brachial plexopathy. Due to worsening symptoms, the patient did
not obtain the MRI and instead presented to the ED for further evaluation. At that time, it was
noted that the patient exhibited 3/5 weakness in both the upper and lower right extremities,
with diminished reflexes. MRI of the brain was obtained, demonstrating a contrast enhancing
4.8 x 4.8 x 5.2 cm mass of the left frontal lobe, with extension to the contralateral frontal lobe
via the body of the corpus callosum. Due to concern for malignancy, specifically glioblastoma
multiforme, CSF studies were obtained and the patient was transferred for brain biopsy. CSF
studies were not suggestive of malignancy or infectious processes, but did reveal elevated IgG
and oligoclonal bands. Pathology from biopsy reported numerous cells with foamy cytoplasm
and diffuse CD68 positivity, as well as loss of myelin with relatively preserved axons on
staining. These results, along with the CSF studies, were suggestive of an inflammatory
demyelinating process, and treatment with steroids was started for suspected tumefactive
multiple sclerosis. Despite an initial positive response to treatment, the patient clinically
declined and was started on disease modifying therapy (DMT), natalizumab.
After several weeks the patient’s symptoms returned, with profound right sided weakness and
new visual deficits. Repeat imaging was obtained and concerning for expansion of the initial
lesion. To help distinguish between tumefactive MS and malignancy, Thallium NM brain
scan was obtained. This failed to show increased uptake that would be suggestive of
malignancy. The patient subsequently improved after additional IV and PO steroid courses, as
well as plasmapheresis, and has since been started on a second DMT (rituximab).

When compared to an earlier CT of the head,
image C, subtle hypoattenuation can be
appreciated. This was commented on by
radiology and further imaging was
recommended at the time.

Lab Results and Pathology
A significant amount of lab work was obtained during the patients workup, almost all of
which was within normal limits. BMP, CBC, LFTs, hepatitis, HIV, syphilis, tuberculin,
autoimmune serology, and inflammatory markers were all unremarkable. Blood and CSF
cultures were obtained at several points and all failed to demonstrate growth. CSF fluid
analysis demonstrated elevated IgG and oligoclonal bands, which were not present in serum
studies. When taken into account with the imaging and pathology report, this highly
suggested a demyelinating process. Pertinent values are noted below.

Discussion
Tumefactive multiple sclerosis is a rare variant of the demyelinating disease, multiple sclerosis
(MS). While MS itself is not uncommon, the prevalence of tumefactive MS is only 1-3 per 1000
cases of MS. At the core of this disease process is an autoimmune mediated destruction of myelin,
though the exact pathogenesis is unclear. The specific location of lesions, and extent of involvement,
will drive symptomatology. The variability of symptoms, along with imaging that typically contains
ring enhancing lesions, necessitates a broad differential and can make diagnosis challenging.
A tumefactive demyelinating lesion (TDL) is the hallmark of tumefactive MS. A TDL is defined as a
tumor-like lesion, typically greater than 2 cm. The ideal imaging modality for identification is MRI
with gadolinium contrast. These lesions exhibit variable amounts of surrounding edema and mass
effect, with ring enhancement that is often incomplete. Lesions are typically hypointense with T1,
and hyperintense with T2 weighted images. Findings that may help to differentiate a TDL from
infectious or malignant etiologies include the presence of more than one lesion, decreased peripheral
diffusion, and incomplete ring enhancement. Incomplete ring enhancement is suggestive of an active
inflammatory process with chronic or quiescing areas of inflammation. Uptake and perfusion
imaging are other modalities that may assist in further differentiation, as TDLs will not show the
same increase of vascularity and metabolic activity as a neoplasm. CT imaging is not diagnostic, but
is typically obtained for individuals presenting with acute neurologic deficits. Hypoattenuation of
TDLs has been commonly described. In the case presented, an initial CT of the head failed to
demonstrate any acute process, but subtle hypoattenuation was noted in an area of distribution
consistent with the later identified lesion. The delay in subsequent MRI contributed to a significant
delay in diagnosis and treatment. Once MRI was obtained, the lesions features were typical for
tumefactive MS, as noted in neuroimaging. Later in the clinical course, the patient underwent
thallium brain scan, which did not show increased uptake, as one would expect with a neoplasm.
Serum and cerebrospinal fluid (CSF) studies can also play an important role in the diagnosis of
tumefactive MS. CSF and serum studies should be obtained to rule out malignant, infectious, or
other inflammatory etiologies. In the case of tumefactive MS, there may be CSF markers suggestive
of a demyelinating process. Elevated IgG and the presence of oligoclonal bands are both suggestive
of this, though not specific to Tumefactive MS. CSF studies in this particular patient did demonstrate
elevated IgG and oligoclonal bands. The remainder of the patient’s serum and CSF studies were
unremarkable.
The diagnosis of tumefactive MS is often possible based on clinical course and typical image
findings. A complicated clinical course or ambiguous imaging may necessitate biopsy for
confirmation. Histopathology of a demyelinating lesion should demonstrate hypercellularity, with
foamy macrophages being the predominant cell type. This is suggested by diffuse CD68 positivity.
There may be reactive astrocytes present, but importantly there should not be coagulative necrosis.
Luxol fast blue staining should demonstrate a loss of myelin, with relatively preserved axons.
Treatment can often be initiated when clinical suspicion is high. First line therapy begins with IV
steroids. In cases that are refractory, plasmapheresis (PLEX) may be indicated. Poor response and
symptom severity may warrant the use of a DMT, such as Rituximab. DMTs have been shown to be
beneficial for MS and delay subsequent clinical attacks, but evidence is insufficient for their use
with first time presentations of TDLs. Interestingly the patient in this case was started on
natalizumab and subsequently deteriorated. Natalizumab use has been associated with TDLs and
could have been a contributing factor for the second clinical event. Once a patient is clinically stable,
subsequent MRIs are important to monitor disease progress and response to treatment.

CSF Studies
Culture: No growth
Fluid Analysis: Protein 91 mg/dL (15-45 mg/dL), IgG 13.5 mg/dL (0.8-7.7 mg/dL),
Oligoclonal bands present with greater than 5 well defined gamma restrictions.

Serum Studies
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